OR WAIT null SECS
Boehringer Ingelheim announces FDA approval of Stiolto Respimat inhaler for the treatment of COPD.
Boehringer Ingelheim announced on May 26, 2015 the approval of Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for chronic obstructive pulmonary disease (COPD), including chronic bronchitis, and/or emphysema. The once-daily treatment was found to improve lung function on a greater scale when compared to the use of tiotropium and olodaterol alone in patients with COPD ranging in severity.
“A recent review of landmark studies indicates that loss of lung function is more accelerated in the early stages of COPD. While no treatment slows the rate of decline, maintenance treatment with Stiolto Respimat initiated at the time of diagnosis will help healthcare providers with their goal of improving lung function,” said Danny McBryan, MD, vice-president, clinical development and medical affairs, respiratory, Boehringer Ingelheim Pharmaceuticals, in a press release.
Source: Boehringer Ingelheim